866-997-4948(US-Canada Toll Free)

Diabetic Nephropathy - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Metabolic Disorders

No. of Pages : 150 Pages


Global Markets Directs, \'Diabetic Nephropathy Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Nephropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy. Diabetic Nephropathy Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diabetic Nephropathy.
  • A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetic Nephropathy pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Nephropathy Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Diabetic Nephropathy 9
Diabetic Nephropathy Therapeutics under Development by Companies 11
Diabetic Nephropathy Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Diabetic Nephropathy Therapeutics - Products under Development by Companies 19
Diabetic Nephropathy Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Diabetic Nephropathy Therapeutics Development 22
Sanofi-Aventis 22
Eli Lilly and Company 23
Questcor Pharmaceuticals, Inc. 24
Daiichi Sankyo Company, Ltd 25
Emergent BioSolutions Inc. 26
Astellas Pharma Inc. 27
Chong Kun Dang Pharmaceutical 28
Mitsubishi Tanabe Pharma Corporation 29
Pfizer Inc. 30
NephroGenex, Inc. 31
Bayer AG 32
GENTIUM S.p.A. 33
Mesoblast Ltd 34
Dongwha Pharm Co., Ltd. 35
PhytoHealth Corporation 36
Angelini Group 37
IMMD Inc. 38
GenKyoTex S.A. 39
Thrasos, Inc. 40
Concert Pharmaceuticals, Inc. 41
NOXXON Pharma AG 42
Intercept Pharmaceuticals, Inc. 43
ChemoCentryx, Inc. 44
Glucox Biotech 45
GNI, LTD. 46
OncoImmune, Inc. 47
Centocor Ortho Biotech, Inc. 48
Fibrotech Therapeutics Pty. Ltd. 49
Ampio Pharmaceuticals, Inc. 50
Diabetic Nephropathy - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
baricitinib - Drug Profile 56
THR-123 - Drug Profile 58
NOX-E-36 - Drug Profile 59
IMD-1041 - Drug Profile 61
DT-23552 - Drug Profile 62
CS-3150 - Drug Profile 63
DW-1029M - Drug Profile 64
GKT-137831 - Drug Profile 65
PF-00489791 - Drug Profile 66
CCX-140 - Drug Profile 68
INT-767 - Drug Profile 70
atrasentan hydrochloride - Drug Profile 72
LY-2382770 - Drug Profile 73
MTP-131 - Drug Profile 74
bindarit - Drug Profile 76
Vasaloc - Drug Profile 78
colchicine - Drug Profile 79
probucol - Drug Profile 80
PF-04634817 - Drug Profile 81
Pyridoxamine Dihydrochloride - Drug Profile 82
GLY-230 - Drug Profile 84
corticotropin zinc hydroxide - Drug Profile 86
CTP-499 - Drug Profile 88
A-717 - Drug Profile 90
MT-3995 - Drug Profile 91
BAY-94-8862 - Drug Profile 92
GR-MD-02 - Drug Profile 93
Drug For Diabetic Nephropathy - Drug Profile 95
TNFR x TWEAKR - Drug Profile 96
cilostazol - Drug Profile 97
pirfenidone - Drug Profile 98
Oligotide - Drug Profile 99
Drug For Diabetic Nephropathy - Drug Profile 100
VPI-2690-B - Drug Profile 101
Program 2 Diabetic Nephropathy - Drug Profile 102
GKT-136901 - Drug Profile 103
FT-011 - Drug Profile 105
NoX-1/4 Inhibitors - Drug Profile 106
Stem Cell Therapy For Diabetic Complications - Drug Profile 107
PHN-033 - Drug Profile 108
HPTPbeta mAb - Drug Profile 109
AKB-9089 - Drug Profile 110
Vascular Endothelial Growth Factor-165B - Drug Profile 111
ASP-8232 - Drug Profile 112
CKD-322 - Drug Profile 113
MG-132 - Drug Profile 114
Mesenchymal Precursor Cells For Diabetic Nephropathy - Drug Profile 116
Diabetic Nephropathy Therapeutics - Drug Profile Updates 118
Diabetic Nephropathy Therapeutics - Discontinued Products 137
Diabetic Nephropathy Therapeutics - Dormant Products 138
Diabetic Nephropathy - Product Development Milestones 139
Featured News & Press Releases 139

Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 147
Disclaimer 147

List of Table


Number of Products Under Development for Diabetic Nephropathy, H2 2013 12
Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2013 13
Number of Products under Development by Companies, H2 2013 15
Number of Products under Development by Companies, H2 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2013 17
Comparative Analysis by Late Stage Development, H2 2013 18
Comparative Analysis by Mid Clinical Stage Development, H2 2013 19
Comparative Analysis by Early Clinical Stage Development, H2 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 21
Products under Development by Companies, H2 2013 22
Products under Development by Companies, H2 2013 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2013 24
Sanofi-Aventis, H2 2013 25
Eli Lilly and Company, H2 2013 26
Questcor Pharmaceuticals, Inc., H2 2013 27
Daiichi Sankyo Company, Ltd, H2 2013 28
Emergent BioSolutions Inc., H2 2013 29
Astellas Pharma Inc., H2 2013 30
Chong Kun Dang Pharmaceutical, H2 2013 31
Mitsubishi Tanabe Pharma Corporation, H2 2013 32
Pfizer Inc., H2 2013 33
NephroGenex, Inc., H2 2013 34
Bayer AG, H2 2013 35
GENTIUM S.p.A., H2 2013 36
Mesoblast Ltd, H2 2013 37
Dongwha Pharm Co., Ltd., H2 2013 38
PhytoHealth Corporation, H2 2013 39
Angelini Group, H2 2013 40
IMMD Inc., H2 2013 41
GenKyoTex S.A., H2 2013 42
Thrasos, Inc., H2 2013 43
Concert Pharmaceuticals, Inc., H2 2013 44
NOXXON Pharma AG, H2 2013 45
Intercept Pharmaceuticals, Inc., H2 2013 46
ChemoCentryx, Inc., H2 2013 47
Glucox Biotech, H2 2013 48
GNI, LTD., H2 2013 49
OncoImmune, Inc., H2 2013 50
Centocor Ortho Biotech, Inc., H2 2013 51
Fibrotech Therapeutics Pty. Ltd., H2 2013 52
Ampio Pharmaceuticals, Inc., H2 2013 53
Assessment by Monotherapy Products, H2 2013 54
Assessment by Stage and Route of Administration, H2 2013 56
Assessment by Stage and Molecule Type, H2 2013 58
Diabetic Nephropathy Therapeutics - Drug Profile Updates 121
Diabetic Nephropathy Therapeutics - Discontinued Products 140
Diabetic Nephropathy Therapeutics - Dormant Products 141

List of Chart


Number of Products under Development for Diabetic Nephropathy, H2 2013 12
Products under Development for Diabetic Nephropathy - Comparative Analysis, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 17
Late Stage Products, H2 2013 18
Mid Clinical Stage Products, H2 2013 19
Early Clinical Stage Products, H2 2013 20
Discovery and Pre-Clinical Stage Products, H2 2013 21
Assessment by Monotherapy Products, H2 2013 54
Assessment by Route of Administration, H2 2013 55
Assessment by Stage and Route of Administration, H2 2013 56
Assessment by Molecule Type, H2 2013 57
Assessment by Stage and Molecule Type, H2 2013 58

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *